LEXX
Lexaria Bioscience Corp.
NASDAQ · Healthcare · Biotechnology · CA
$14.15
+14.85%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 194.0K | 705.9K | 464.3K | 226.2K | 255.4K |
| Cost of Revenue | — | 2.7K | 4.8K | 31.5K | 71.8K |
| Gross Profit | 194.0K | 703.2K | 459.5K | 194.7K | 183.6K |
| Operating Expenses | |||||
| R&D Expense | 4.0M | 8.2M | 2.4M | 3.7M | 1.8M |
| SG&A Expense | 3.9M | 4.3M | 3.9M | 3.1M | 5.0M |
| General & Admin Expense | 3.9M | 4.3M | 3.9M | 3.1M | 5.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 7.9M | 12.6M | 6.2M | 6.7M | 6.8M |
| Cost and Expenses | 7.9M | 12.6M | 6.2M | 6.8M | 6.9M |
| Operating Income (EBIT) | (7.7M) | (11.9M) | (5.8M) | (6.5M) | (6.6M) |
| Non-Operating | |||||
| Interest Income | 5.4K | 3.0K | 14.3K | 43.2K | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 5.4K | 3.0K | 14.3K | 43.2K | — |
| Other Non-Op Income/Expense | (28.1K) | (30.7K) | (55.5K) | (178.5K) | (764.6K) |
| Non-Operating Income (excl Interest) | 28.1K | 30.7K | 55.5K | 178.5K | 764.6K |
| EBT (Pre-Tax Income) | (7.7M) | (11.9M) | (5.8M) | (6.7M) | (7.4M) |
| Income Tax Expense | 4.4K | — | — | — | — |
| Bottom Line | |||||
| Net Income | (7.7M) | (11.9M) | (5.8M) | (6.7M) | (7.3M) |
| Earnings from Cont. Ops | (7.7M) | (11.9M) | (5.8M) | (6.7M) | (7.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.7M) | (11.9M) | (5.8M) | (6.7M) | (7.3M) |
| Per Share | |||||
| Basic EPS | ($5.32) | ($9.90) | ($7.05) | ($15.15) | ($18.60) |
| Diluted EPS | ($5.32) | ($9.90) | ($7.05) | ($15.15) | ($18.60) |
| Revenue Per Share | $0.12 | $0.59 | $0.56 | $0.51 | $0.65 |
| Shares | |||||
| Basic Shares Outstanding | 1.7M | 1.2M | 825598 | 440938 | 392350 |
| Diluted Shares Outstanding | 1.7M | 1.2M | 825598 | 440938 | 392350 |
| Profitability Metrics | |||||
| EBITDA | (7.7M) | (11.8M) | (5.7M) | (6.6M) | (7.3M) |
| D&A | 57.4K | 87.8K | 76.2K | 145.4K | 102.7K |
| EBIT | (7.7M) | (11.9M) | (5.8M) | (6.7M) | (7.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of May 1, 2026